David Fawks
Psychiatric/Mental Health · Venice, FLNPI 1922094937
Payments from drug & device makers
Across 340 payments — averaging $25.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Neurocrine Biosciences, Inc.$833
- Axsome Therapeutics, Inc.$571
- Johnson & Johnson$555
- plus $3K from 18 others
What the payments were for
- Food & beverage$8,686100%
- Education$360%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 54 | $1,184 |
| Otsuka America Pharmaceutical, Inc. | 41 | $1,090 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 32 | $1,016 |
| Neurocrine Biosciences, Inc. | 27 | $833 |
| Axsome Therapeutics, Inc. | 18 | $571 |
| Johnson & Johnson | 18 | $555 |
| Alkermes, Inc. | 20 | $544 |
| Teva Pharmaceuticals USA, Inc. | 18 | $444 |
| Almatica Pharma LLC | 20 | $335 |
| E.r. Squibb & Sons, L.L.C. | 7 | $319 |
| Lundbeck LLC | 9 | $307 |
| Corium, LLC | 15 | $228 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $221 |
| Noven Therapeutics, LLC | 11 | $188 |
| Supernus Pharmaceuticals, Inc. | 7 | $186 |
| Vanda Pharmaceuticals Inc. | 7 | $186 |
| Idorsia Pharmaceuticals US Inc | 9 | $173 |
| Bausch Health US, LLC | 6 | $126 |
| Merck | 6 | $111 |
| Neos Therapeutics, LP | 2 | $32 |
| Tris Pharma Inc | 1 | $24 |
| Validus Pharmaceuticals LLC | 1 | $20 |
| Tonix Medicines, Inc. | 1 | $16 |
| TMS Neurohealth Centers Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,721 in reported general payments places this provider in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 37 | $310,079 |
| VraylarCariprazine Hcl | 84 | $150,328 |
| Austedo XrDeutetrabenazine | 23 | $138,891 |
| RexultiBrexpiprazole | 59 | $93,624 |
| AuvelityDextromethorphan Hbr/Bupropion | 41 | $54,498 |
| TrintellixVortioxetine Hydrobromide | 61 | $40,956 |
| AplenzinBupropion Hbr | 12 | $30,512 |
| Lurasidone Hcl | 82 | $13,526 |
| Vilazodone Hcl | 86 | $11,816 |
| FetzimaLevomilnacipran Hcl | 13 | $11,626 |
| Aripiprazole | 129 | $11,534 |
| BelsomraSuvorexant | 25 | $10,707 |
| Loreev XrLorazepam | 20 | $8,781 |
| Duloxetine Hcl | 330 | $8,254 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 182 | $8,214 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $833 | $310,07937 claims |
| AbbVieVraylar, Fetzima | $1,184 | $161,95397 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $444 | $138,89123 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,090 | $93,62459 claims |
| Axsome Therapeutics, Inc.Auvelity | $571 | $54,49841 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $221 | $40,95661 claims |
| Bausch Health US, LLCAplenzin | $126 | $30,51212 claims |
| MerckBelsomra | $111 | $10,70725 claims |
| Almatica Pharma LLCLoreev Xr, Sertraline Hcl | $335 | $10,340254 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Other psychiatric/mental health in Venice
- Roger RiveraKissimmee$1.6M
- Bethanie Simmons BecilJacksonville$782K
- Hannah PhillipsMaitland$455K
- Cheedy JajaTampa$266K
- Scott DurrancePensacola$224K
- Eudaldo AponteHialeah$214K
- Heather WarrenTallahassee$172K
- Angela DavenportAlachua$83K
- Natalie MoodyWinter Haven$75K
- Kelli BridgmanNew Smyrna Beach$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.